MA38400A1 - Molécules fc bispécifiques - Google Patents
Molécules fc bispécifiquesInfo
- Publication number
- MA38400A1 MA38400A1 MA38400A MA38400A MA38400A1 MA 38400 A1 MA38400 A1 MA 38400A1 MA 38400 A MA38400 A MA 38400A MA 38400 A MA38400 A MA 38400A MA 38400 A1 MA38400 A1 MA 38400A1
- Authority
- MA
- Morocco
- Prior art keywords
- molecules
- bispecific
- methods
- nucleic acids
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne une molécule bispécifique contenant une chaîne polypeptidique fc et des domaines variables d'immunoglobuline. La présente invention concerne également des formules pharmaceutiques comprenant lesdites molécules, des acides nucléiques codant lesdites molécules, des cellules hôtes contenant lesdits acides nucléiques, des procédés de fabrication desdites molécules et des procédés d'utilisation desdites molécules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791424P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/029253 WO2014144722A2 (fr) | 2013-03-15 | 2014-03-14 | Molécules fc bispécifiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA38400A1 true MA38400A1 (fr) | 2017-09-29 |
Family
ID=50489434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38400A MA38400A1 (fr) | 2013-03-15 | 2014-03-14 | Molécules fc bispécifiques |
Country Status (21)
Country | Link |
---|---|
US (5) | US20140302037A1 (fr) |
EP (1) | EP2970477B1 (fr) |
JP (2) | JP6535654B2 (fr) |
KR (1) | KR20150139531A (fr) |
CN (1) | CN105229031A (fr) |
AP (1) | AP2015008773A0 (fr) |
AU (1) | AU2014228829B2 (fr) |
BR (1) | BR112015023431A2 (fr) |
CA (1) | CA2902961C (fr) |
CL (1) | CL2015002756A1 (fr) |
CR (1) | CR20150573A (fr) |
EA (1) | EA201591814A1 (fr) |
HK (1) | HK1214275A1 (fr) |
IL (1) | IL241354A0 (fr) |
MA (1) | MA38400A1 (fr) |
MX (2) | MX2015012187A (fr) |
PE (1) | PE20151998A1 (fr) |
PH (1) | PH12015502083A1 (fr) |
SG (1) | SG11201506647SA (fr) |
TN (1) | TN2015000379A1 (fr) |
WO (1) | WO2014144722A2 (fr) |
Families Citing this family (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012355435A1 (en) * | 2011-12-21 | 2014-07-17 | Amgen Inc. | Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor |
CN104640562A (zh) * | 2012-07-13 | 2015-05-20 | 酵活有限公司 | 包含抗-cd3构建体的双特异性不对称异二聚体 |
AU2014236769B2 (en) * | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
ES2777940T3 (es) | 2013-05-03 | 2020-08-06 | Ohio State Innovation Foundation | Células efectoras inmunitarias genomanipuladas con un receptor de antígeno químico específico de CS1 |
MX2016006572A (es) | 2013-11-27 | 2016-12-09 | Zymeworks Inc | Construcciones de union a antigenos biespecificas dirigidas a her2. |
UA120753C2 (uk) | 2013-12-17 | 2020-02-10 | Дженентек, Інк. | Біспецифічне антитіло до сd3 та cd20 |
KR102568808B1 (ko) | 2014-04-07 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 면역활성화 항원 결합 분자 |
JP6894702B2 (ja) * | 2014-05-13 | 2021-06-30 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子 |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
WO2016014974A2 (fr) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps |
AU2015294834B2 (en) | 2014-07-31 | 2021-04-29 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
AU2015323313B2 (en) * | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
EP4141032B1 (fr) | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Thérapie combinée de molécules de liaison à l'antigène spécifiques d'activation des lymphocytes t et d'antagonistes de liaison à l'axe d-1 |
JP2018510623A (ja) * | 2015-02-20 | 2018-04-19 | オハイオ・ステイト・イノベーション・ファウンデーション | Nkg2d及び腫瘍関連抗原に対する二価抗体 |
EP3280437A4 (fr) | 2015-04-06 | 2018-09-12 | Jianhua Yu | Thérapie du car ciblant l'egfr contre le glioblastome |
LT3283524T (lt) | 2015-04-17 | 2023-05-25 | Amgen Research (Munich) Gmbh | Bispecifiniai antikūnų konstruktai, skirti cdh3 ir cd3 |
JP2018520642A (ja) * | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | マスク抗cd3抗体及びその使用方法 |
WO2016182064A1 (fr) * | 2015-05-13 | 2016-11-17 | 中外製薬株式会社 | Molécule de fusion possédant la capacité à se lier à plusieurs antigènes, composition pharmaceutique, méthode d'identification d'épitopes linéaires, et méthode de préparation de la molécule de fusion possédant la capacité à se lier à plusieurs antigènes |
EP3932428A1 (fr) | 2015-05-21 | 2022-01-05 | Harpoon Therapeutics, Inc. | Protéines trispécifiques de liaison et méthodes d'utilisation |
WO2017011414A1 (fr) * | 2015-07-10 | 2017-01-19 | Duke University | Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1 |
WO2017011413A1 (fr) * | 2015-07-10 | 2017-01-19 | Duke University | Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1 |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
CN107921130A (zh) * | 2015-08-17 | 2018-04-17 | 宏观基因有限公司 | 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途 |
MA43025A (fr) * | 2015-10-02 | 2021-05-26 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3 |
WO2017055388A2 (fr) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t |
AU2016347058B2 (en) | 2015-10-25 | 2023-11-09 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection |
CN107207608B (zh) * | 2015-10-30 | 2021-05-11 | 江苏众红生物工程创药研究院有限公司 | 双特异性抗体、其制备方法和用途 |
WO2017086419A1 (fr) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | Procédé pour renforcer la réponse immunitaire humorale |
JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
BR112018003984A2 (pt) | 2015-12-09 | 2018-09-25 | Hoffmann La Roche | anticorpos |
PL3400246T3 (pl) | 2016-01-08 | 2021-03-08 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
KR20180101623A (ko) | 2016-02-03 | 2018-09-12 | 암젠 리서치 (뮌헨) 게엠베하 | Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물 |
EP3411402B1 (fr) | 2016-02-03 | 2021-12-22 | Amgen Research (Munich) GmbH | Anticorps anti-bcma et anti-cd3 bispécifiques de format bite |
US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
WO2017162587A1 (fr) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Molécules bispécifiques de cellules t activées par une protéase |
DK3433280T3 (da) | 2016-03-22 | 2023-06-19 | Hoffmann La Roche | Protease-aktiverede T-celle-bispecifikke molekyler |
DK3443006T5 (da) | 2016-04-13 | 2023-11-06 | Sanofi Sa | Trispecifikke og/eller trivalente bindingsproteiner |
SG11201808911SA (en) * | 2016-04-13 | 2018-11-29 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
WO2017194597A1 (fr) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Matrice de séparation |
EP3455241B1 (fr) | 2016-05-11 | 2022-02-23 | Cytiva BioProcess R&D AB | Procédé de nettoyage et/ou de désinfection d'une matrice de séparation |
CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR102365977B1 (ko) | 2016-05-20 | 2022-02-22 | 하푼 테라퓨틱스, 인크. | 단일 쇄 가변 단편 cd3 결합 단백질 |
AU2017297603A1 (en) | 2016-07-14 | 2019-02-14 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
AU2017298984B2 (en) | 2016-07-22 | 2023-08-31 | Amgen Inc. | Methods of purifying Fc-containing proteins |
EP3541843A1 (fr) | 2016-11-15 | 2019-09-25 | Genentech, Inc. | Dosage pour le traitement avec des anticorps bispécifiques anti-cd20/anti-cd3 |
MX2019006045A (es) | 2016-11-23 | 2019-11-11 | Harpoon Therapeutics Inc | Proteinas triespecificas dirigidas a psma y metodos de uso. |
EP3544997A4 (fr) | 2016-11-23 | 2020-07-01 | Harpoon Therapeutics, Inc. | Protéine de liaison à l'antigène membranaire spécifique de la prostate |
JOP20190189A1 (ar) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
EP3589662A4 (fr) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | Protéine monovalente inductible de fixation d' antigène |
KR20190141243A (ko) | 2017-05-05 | 2019-12-23 | 암젠 인크 | 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물 |
CN115028727A (zh) | 2017-05-12 | 2022-09-09 | 哈普恩治疗公司 | 靶向msln的三特异性蛋白质及使用方法 |
AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018222901A1 (fr) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à une protéine de leucémie myéloproliférative (mpl) et leurs utilisations |
WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
AU2018347582A1 (en) | 2017-10-13 | 2020-05-07 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
US10927180B2 (en) | 2017-10-13 | 2021-02-23 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
KR20200064096A (ko) | 2017-10-14 | 2020-06-05 | 싸이톰스 테라퓨틱스, 인크. | 항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법 |
TWI827570B (zh) | 2017-12-11 | 2024-01-01 | 美商安進公司 | 雙特異性抗體產品之連續製造製程 |
TW201940518A (zh) | 2017-12-29 | 2019-10-16 | 美商安進公司 | 針對muc17和cd3之雙特異性抗體構建體 |
CA3089287A1 (fr) | 2018-02-08 | 2019-08-15 | Genentech, Inc. | Molecules bispecifiques de liaison a l'antigene et procedes d'utilisation |
JP7433236B2 (ja) | 2018-03-13 | 2024-02-19 | フェインズ セラピューティクス,インコーポレーテッド | 抗葉酸受容体1抗体及びその使用 |
US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019178364A2 (fr) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles et utilisations associées |
EP3773657A4 (fr) * | 2018-03-26 | 2021-12-08 | Altor Bioscience LLC | Molécules d'association au récepteur du tgf-beta, il-15 et anti-pdl1 |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
EP3830121A1 (fr) | 2018-07-30 | 2021-06-09 | Amgen Research (Munich) GmbH | Administration prolongée d'une construction d'anticorps bispécifique se liant à cd33 et cd3 |
WO2020025596A1 (fr) | 2018-07-31 | 2020-02-06 | Amgen Research (Munich) Gmbh | Régime posologique pour anticorps bispécifiques bcma-cd3 |
BR112021002032A2 (pt) | 2018-08-03 | 2021-07-20 | Amgen Research (Munich) Gmbh | construtos de anticorpos para cldn18.2 e cd3 |
KR20210086623A (ko) | 2018-09-25 | 2021-07-08 | 하푼 테라퓨틱스, 인크. | Ddl3 결합 단백질 및 사용 방법 |
EP3856764A4 (fr) * | 2018-09-27 | 2022-11-02 | Xilio Development, Inc. | Polypeptides de cytokine masqués |
UY38393A (es) | 2018-09-28 | 2020-03-31 | Amgen Inc | Anticuerpos contra bcma soluble |
JP2022512636A (ja) | 2018-10-11 | 2022-02-07 | アムジエン・インコーポレーテツド | 二重特異性抗体コンストラクトの下流プロセシング |
US20220119533A1 (en) * | 2018-10-23 | 2022-04-21 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
US20220128474A1 (en) | 2018-10-23 | 2022-04-28 | Amgen Inc. | Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions |
US11965030B2 (en) | 2018-12-24 | 2024-04-23 | Sanofi | Multispecific binding proteins with mutant fab domains |
TW202043253A (zh) | 2019-01-28 | 2020-12-01 | 美商安進公司 | 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程 |
CA3130508A1 (fr) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Molecules d'anticorps se liant a nkp30 et utilisations associees |
CN114127113A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与钙网蛋白结合的多功能分子及其用途 |
EP3927744A1 (fr) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations |
SG11202109033XA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
SG11202109122SA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Anti-tcr antibody molecules and uses thereof |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
EP3983520A1 (fr) | 2019-06-13 | 2022-04-20 | Amgen, Inc | Commande de perfusion contenant de la biomasse automatisée dans la fabrication de produits biologiques |
JP2022547135A (ja) | 2019-09-10 | 2022-11-10 | アムジエン・インコーポレーテツド | 増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法 |
WO2021091906A1 (fr) | 2019-11-04 | 2021-05-14 | Amgen Inc. | Procédé de traitement de la leucémie |
EP3819007A1 (fr) | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Régime de dosage pour agents anti-bcma |
WO2021097344A1 (fr) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Procédé de réduction de la formation d'agrégats dans le traitement en aval de molécules de liaison à l'antigène bispécifiques |
WO2021119505A1 (fr) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anticorps anti-ly6g6d et méthodes d'utilisation |
UY38995A (es) | 2019-12-20 | 2021-06-30 | Amgen Inc | Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos |
EP4084821A4 (fr) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics Inc | Molécules multifonctionnelles se liant à cd33 et utilisations associées |
EP4093771A1 (fr) | 2020-01-22 | 2022-11-30 | Amgen Research (Munich) GmbH | Combinaisons de constructions d'anticorps et d'inhibiteurs du syndrome de libération de cytokine et leurs utilisations |
WO2021158469A1 (fr) | 2020-02-03 | 2021-08-12 | Amgen Inc. | Approche d'encadrement à plusieurs variables pour la validation d'un filtre stérile |
WO2021168303A1 (fr) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Protéines de liaison à flt3 et méthodes d'utilisation |
TW202200615A (zh) | 2020-03-12 | 2022-01-01 | 美商安進公司 | 用於治療和預防患者的crs之方法 |
IL296601A (en) | 2020-03-19 | 2022-11-01 | Amgen Inc | Antibodies against mucin 17 and their uses |
AU2021261420A1 (en) | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
US20220017636A1 (en) | 2020-05-19 | 2022-01-20 | Amgen Inc. | Mageb2 binding constructs |
TW202210101A (zh) | 2020-05-29 | 2022-03-16 | 美商安進公司 | 與cd33和cd3結合的雙特異性構建體的減輕不良反應投與 |
CA3190755A1 (fr) | 2020-08-26 | 2022-03-03 | Andreas Loew | Molecules multifonctionnelles se liant a la calreticuline et utilisations associees |
KR20230074144A (ko) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | NKp30에 결합하는 항체 분자 및 이의 용도 |
AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
WO2022060878A1 (fr) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Méthodes de traitement du cancer de la prostate |
EP4214233A1 (fr) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer |
BR112023008629A2 (pt) | 2020-11-06 | 2023-10-03 | Amgen Inc | Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3 |
EP4240768A2 (fr) | 2020-11-06 | 2023-09-13 | Amgen Inc. | Molécules bispécifiques multicibles de liaison à un antigène à sélectivité accrue |
US20230406887A1 (en) | 2020-11-06 | 2023-12-21 | Amegen Inc. | Antigen binding domain with reduced clipping rate |
CN116635421A (zh) | 2020-11-06 | 2023-08-22 | 安进公司 | 与cd3结合的多肽构建体 |
WO2022103781A1 (fr) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Procédés d'administration d'une molécule de liaison à bcma x cd3 |
TW202233684A (zh) * | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
EP4263600A1 (fr) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Systèmes récepteurs antigéniques chimériques ayant une spécificité de récepteur adaptable |
HUP2100038A1 (hu) * | 2021-02-03 | 2022-08-28 | Richter Gedeon Nyrt | Mutáltatott rekombináns ACE2-Fc fúziós fehérjék COVID-19 fertõzések kezelésére |
JP2024509878A (ja) | 2021-03-10 | 2024-03-05 | アムジエン・インコーポレーテツド | パラレルクロマトグラフィーシステム及び方法 |
KR20230154908A (ko) | 2021-03-10 | 2023-11-09 | 암젠 인크 | 재조합 단백질의 정제 방법 |
AR125290A1 (es) | 2021-04-02 | 2023-07-05 | Amgen Inc | Construcciones de unión a mageb2 |
GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
WO2022234102A1 (fr) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Molécules de liaison à l'antigène ciblant cd20 et cd22 destinées à être utilisées dans des maladies prolifératives |
TW202317625A (zh) | 2021-06-17 | 2023-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 新穎三特異性結合分子 |
CN113337514B (zh) * | 2021-08-05 | 2021-10-29 | 卡瑞济(北京)生命科技有限公司 | Tcr表达构建体以及其制备方法和用途 |
US20230183382A1 (en) * | 2021-10-15 | 2023-06-15 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
WO2023076318A1 (fr) | 2021-10-27 | 2023-05-04 | Amgen Inc. | Prédiction fondée sur un apprentissage profond pour la surveillance de produits pharmaceutiques par spectroscopie |
TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
CA3237018A1 (fr) | 2021-11-03 | 2023-05-11 | Joachim Koch | Liants de cd16a bispecifiques |
WO2023164288A2 (fr) | 2022-02-28 | 2023-08-31 | Xilio Development, Inc. | Cytokines ciblées et leurs méthodes d'utilisation |
WO2023164286A1 (fr) | 2022-02-28 | 2023-08-31 | Xilio Development, Inc. | Compositions de cd122 modifiées et procédés associés |
WO2023218027A1 (fr) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Molécules bispécifiques multicibles à chaînes multiples de liaison à un antigène à sélectivité accrue |
WO2024015960A1 (fr) | 2022-07-15 | 2024-01-18 | Xilio Development, Inc. | Domaine fc clivable modifié utilisé en tant que porteurs et ses procédés d'utilisation |
WO2024059675A2 (fr) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Composition de stabilisation de molécule bispécifique |
WO2024077044A1 (fr) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Polythérapies comprenant des thérapies de redirection de lymphocytes t et des anticorps agonistes anti-il-2r ou des fragments de ceux-ci |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
KR100508289B1 (ko) * | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Cd19×cd3 특이 폴리펩티드 및 그의 용도 |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2357187A1 (fr) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molécules à demi-vies longues, compositions et utilisations de celles-ci |
CN1195779C (zh) * | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
JP4966497B2 (ja) * | 2002-11-15 | 2012-07-04 | ゲンマブ エー/エス | Cd25に対するヒトモノクローナル抗体 |
JP2008501621A (ja) * | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物 |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
EP2006379B1 (fr) * | 2006-03-23 | 2016-08-31 | Tohoku University | Anticorps bispecifique hautement fonctionnel |
KR101626988B1 (ko) * | 2007-04-03 | 2016-06-02 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 이중특이적인 결합제들 |
WO2008119567A2 (fr) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Domaine de liaison spécifique d'espèces croisées |
HUE040467T2 (hu) * | 2007-04-03 | 2019-03-28 | Amgen Res Munich Gmbh | Keresztfaj-specifikus kötõdomén |
WO2009018386A1 (fr) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Protéines de liaison à épitope multispécifiques et leurs utilisations |
EP2050764A1 (fr) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
ES2445755T3 (es) * | 2007-11-07 | 2014-03-05 | Celldex Therapeutics, Inc. | Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205) |
BRPI0821906B1 (pt) * | 2008-01-03 | 2022-06-07 | The Scripps Research Institute | Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
EP3002299A1 (fr) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Immunoglobulines à deux domaines variables et leurs utilisations |
EP2352763B2 (fr) * | 2008-10-01 | 2022-09-21 | Amgen Research (Munich) GmbH | Anticorps monocaténaires bispécifiques spécifiques d'antigènes cibles de masse moléculaire élevée |
EP2504360B1 (fr) * | 2009-11-23 | 2018-08-15 | Amgen Inc. | Anticorps monomère fc |
EP2516458A1 (fr) * | 2009-12-22 | 2012-10-31 | Novartis AG | Protéine hybride tétravalente à région constante d'anticorps anti-cd-47 à utiliser en thérapie |
MY171234A (en) * | 2010-02-24 | 2019-10-04 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
US20140112926A1 (en) | 2011-03-16 | 2014-04-24 | Amgen Inc. | Fc VARIANTS |
TWI803876B (zh) * | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
IL303208A (en) * | 2011-04-01 | 2023-07-01 | Immunogen Inc | Methods for increasing the effectiveness of FOLR1 cancer therapy |
WO2012143524A2 (fr) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Anticorps bispécifiques contre her2 et cd3 |
US20130078250A1 (en) * | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
DK2766392T3 (da) * | 2011-10-10 | 2019-10-07 | Xencor Inc | Fremgangsmåde til oprensning af antistoffer |
CA2854806A1 (fr) * | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Proteines de liaison multispecifiques et multivalentes et leurs utilisations |
AU2012355435A1 (en) | 2011-12-21 | 2014-07-17 | Amgen Inc. | Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
-
2014
- 2014-03-13 US US14/210,178 patent/US20140302037A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029253 patent/WO2014144722A2/fr active Application Filing
- 2014-03-14 US US14/774,309 patent/US20160145340A1/en not_active Abandoned
- 2014-03-14 BR BR112015023431A patent/BR112015023431A2/pt not_active Application Discontinuation
- 2014-03-14 AP AP2015008773A patent/AP2015008773A0/xx unknown
- 2014-03-14 CA CA2902961A patent/CA2902961C/fr active Active
- 2014-03-14 EP EP14717954.3A patent/EP2970477B1/fr active Active
- 2014-03-14 KR KR1020157028764A patent/KR20150139531A/ko not_active Application Discontinuation
- 2014-03-14 MX MX2015012187A patent/MX2015012187A/es unknown
- 2014-03-14 CN CN201480027445.7A patent/CN105229031A/zh active Pending
- 2014-03-14 PE PE2015002013A patent/PE20151998A1/es not_active Application Discontinuation
- 2014-03-14 EA EA201591814A patent/EA201591814A1/ru unknown
- 2014-03-14 MA MA38400A patent/MA38400A1/fr unknown
- 2014-03-14 AU AU2014228829A patent/AU2014228829B2/en active Active
- 2014-03-14 JP JP2016503027A patent/JP6535654B2/ja active Active
- 2014-03-14 SG SG11201506647SA patent/SG11201506647SA/en unknown
-
2015
- 2015-08-31 TN TN2015000379A patent/TN2015000379A1/en unknown
- 2015-09-09 IL IL241354A patent/IL241354A0/en unknown
- 2015-09-10 MX MX2021010416A patent/MX2021010416A/es unknown
- 2015-09-11 PH PH12015502083A patent/PH12015502083A1/en unknown
- 2015-09-15 CL CL2015002756A patent/CL2015002756A1/es unknown
- 2015-10-15 CR CR20150573A patent/CR20150573A/es unknown
-
2016
- 2016-02-25 HK HK16102153.1A patent/HK1214275A1/zh unknown
-
2018
- 2018-02-01 US US15/885,998 patent/US11753475B2/en active Active
- 2018-07-11 US US16/032,342 patent/US20190002568A1/en not_active Abandoned
-
2019
- 2019-03-28 JP JP2019062358A patent/JP6732988B2/ja active Active
-
2022
- 2022-03-17 US US17/697,632 patent/US20230212297A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38400A1 (fr) | Molécules fc bispécifiques | |
EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
EA201890630A1 (ru) | Антитела против pd-1 и способы их применения | |
MA40972B1 (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
EA201890790A1 (ru) | Связывающие pd-1 белки и способы их применения | |
MA38308B1 (fr) | Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t | |
EA201492101A1 (ru) | Антитела против fcrn | |
EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
EA200870021A1 (ru) | Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител | |
EA201990017A1 (ru) | Антитела к миостатину и способы их применения | |
EA200800229A1 (ru) | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) | |
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
EA200870020A1 (ru) | Человеческие моноклональные антитела против о8е | |
CY1113089T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma) | |
UA115657C2 (uk) | Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла | |
EA201791841A1 (ru) | Новые белки, специфичные к пиовердину и пиохелину | |
UA115402C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським | |
EA201791393A2 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения |